BioWorld Asia

Sep. 11, 2002

Kudos Raises £30M For Clinical Development Of Cancer Drugs

LONDON - Kudos Pharmaceuticals Ltd. raised £29.5 million (US$45.9 million) in third-round funding with plans to take its two lead cancer treatments through Phase II and push further compounds into Phase I. (Bioworld International Read More

With New Premises, Tropos Launches € 15M Funding Round

No Abstract Read More

Gene Deletion From Colorectal Tumors Might Dictate Success

Session Examines Avoiding Legal Pitfalls In Clinical Trials

Committee Provides Support For European Biotechnology

EU Legislation On GMO Exports Weak, Parliament Member Says

Medivir To Lose CEO Frick To Venture Capital Fund

MediGene Reports Positive Early Results In Liver Cancer

Avidex Third Round Raises £11.5M For T-Cell Receptors

New Controls On Genetically Modified Animals Needed In UK

ScanBalt BioRegion Looking To Create Global Biotech Region

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 8, 2026.

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

BioWorld Science

Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...